◎ Sugi Atlas

Atlas / Drug / Methylprednisolone

Methylprednisolone

drug
On this page

Also known as J3.872EMedrolMedroneMetilprednisolonaNSC-19987U-67,590A6methylprednisoloneSID855789SID56424125SID82706SID144203927SID144212335SID170465051C0164990

Summary

Methylprednisolone (CHEMBL650) is an approved small-molecule anti-inflammatory drug (ATC H02BX01) targeting TRPC5 and NR3C1; indicated across 156 conditions including acne and crohn disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: H02BX01 (+3 more)
  • Targets: 2 (TRPC5, NR3C1)
  • Indications: 156 conditions
  • Clinical trials: 614
  • Chemistry: 374.5 Da · C22H30O5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL650
NameMethylprednisolone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID6741
ChEBICHEBI:6888
ATCH02BX01, D07AA01, D10AA02, H02AB04
Molecular formulaC22H30O5
Molecular weight374.5
InChIKeyVHRSUDSXCMQTMA-PJHHCJLFSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O

IUPAC name: (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

ChEBI definition: The 6α-stereoisomer of 6-methylprednisolone.

Pharmacological roles (ChEBI): anti-inflammatory drug, neuroprotective agent, antiemetic, adrenergic agent.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: J3.872E, Medrol, Medrone, Methylprednisolone, Metilprednisolona, NSC-19987, U-67,590A, methylprednisolone, 6methylprednisolone, SID855789, METHYLPREDNISOLONE, SID56424125

Parent form; salt/anhydrous children: CHEMBL1200844

Patent coverage: 25,542 distinct patent families (97,827 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TRPC5TRPC5Activation4.920%Q9UL62
NR3C1Glucocorticoid receptorAgonist8.30.9%P04150

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, Glucocorticoid receptor, Progesterone receptor, Nuclear receptor subfamily 1 group I member 2, 3’,5’-cyclic-AMP phosphodiesterase 4D, Androgen receptor, Nuclear receptor subfamily 1 group I member 2, Hypoxia-inducible factor 1-alpha, Bile salt export pump.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C18.3Ki5.03nMCHEMBL_ACT_7777363
NR3C18.05AC509nMCHEMBL_ACT_25176334
NR3C17.96IC5011nMCHEMBL_ACT_7777362
HIF1A7.3Potency50.1nMCHEMBL_ACT_4129624
HIF1A7.3Potency50.1nMCHEMBL_ACT_4518660
PGR5.89AC501300nMCHEMBL_ACT_25223456
Q9R1A75.4EC504000nMCHEMBL_ACT_15463834

Target pathways

Aggregated over 2 target gene(s): TRPC5, NR3C1.

Top Reactome pathways

10 total, by targets touching each:

PathwayTargetsGenes
TRP channels1TRPC5
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
Role of second messengers in netrin-1 signaling1TRPC5
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
calcium ion transport1
positive regulation of cytosolic calcium ion concentration1
nervous system development1
positive regulation of cell population proliferation1
neuron differentiation1
positive regulation of neuron differentiation1
positive regulation of axon extension1
negative regulation of dendrite morphogenesis1
neuron apoptotic process1
regulation of cytosolic calcium ion concentration1
calcium ion transmembrane transport1
phosphatidylserine exposure on apoptotic cell surface1
regulation of membrane hyperpolarization1
monoatomic ion transport1
monoatomic ion transmembrane transport1

Indications & clinical

Indications

156 indications (17 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
acne4MONDO:0011438EFO:0003894
Crohn disease4MONDO:0005011EFO:0000384
rheumatoid arthritis4MONDO:0008383EFO:0000685
frozen shoulder4MONDO:0006763EFO:1000941
ulcerative colitis4MONDO:0005101EFO:0000729
pneumonia4MONDO:0005249EFO:0003106
atopic eczema4MONDO:0004980EFO:0000274
psoriatic arthritis4MONDO:0011849EFO:0003778
tenosynovitis4MONDO:0004855EFO:1001435
asthma4MONDO:0004979MONDO:0004979
osteoarthritis4MONDO:0005178MONDO:0005178
multiple sclerosis4MONDO:0005301MONDO:0005301
endocrine system disorder4MONDO:0005151EFO:0001379
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
posterior uveitis4MONDO:0006918EFO:1001119
bursitis4MONDO:0002471MONDO:0002471
relapsing-remitting multiple sclerosis3MONDO:0005314EFO:0003929
Meniere disease3MONDO:0007972EFO:0006862
graft versus host disease3MONDO:0013730EFO:0004599
chronic progressive multiple sclerosis3MONDO:0005284EFO:0003840
plasma cell myeloma3MONDO:0009693EFO:0001378
respiratory system disorder3MONDO:0005087EFO:0000684
carpal tunnel syndrome3MONDO:0007275EFO:0004143
urinary tract infection3MONDO:0100338EFO:0003103
anterior ischemic optic neuropathy3MONDO:0006649EFO:1000809
lymphoid neoplasm3MONDO:0005157EFO:0001642
kidney disorder3MONDO:0005240EFO:0003086
autoimmune thrombocytopenic purpura3MONDO:0008558EFO:0007160
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
juvenile dermatomyositis3MONDO:0008054EFO:0000557
leukemia3MONDO:0005059EFO:0000565
lymphoma3MONDO:0005062EFO:0000574
systemic sclerosis3MONDO:0005100EFO:0000717
heart disorder3MONDO:0005267EFO:0003777
chronic kidney disease3MONDO:0005300EFO:0003884
IgA glomerulonephritis3MONDO:0005342EFO:0004194
membranous glomerulonephritis3MONDO:0005376EFO:0004254
anti-neutrophil antibody associated vasculitis3MONDO:0005435EFO:0004826
granulomatosis with polyangiitis3MONDO:0012105EFO:0005297
lupus nephritis3MONDO:0005556EFO:0005761
Bell’s palsy3MONDO:0005665EFO:0007167
vestibular neuronitis3MONDO:0006008EFO:0007537
acute respiratory distress syndrome3MONDO:0006502EFO:1000637
microscopic polyangiitis3MONDO:0019124EFO:1000784
spinal cord injury3MONDO:0043797EFO:1001919
thrombocytopenia3MONDO:0002049HP:0001873
cardiac arrest3MONDO:0000745EFO:0009492
T-cell acute lymphoblastic leukemia3MONDO:0004963EFO:0000209
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
optic neuritis3MONDO:0005885EFO:0007405
pneumocystosis3MONDO:0019121EFO:0007448
pulpitis3MONDO:0006937EFO:1001139
specific language disorder3MONDO:0016226MONDO:0016226
hematopoietic and lymphoid system neoplasm3MONDO:0002334MONDO:0044881
Hodgkins lymphoma3MONDO:0004952MONDO:0009348
adult acute respiratory distress syndrome3MONDO:0100130MONDO:0100130
primary progressive multiple sclerosis3MONDO:0000451EFO:0008520
myocarditis3MONDO:0004496EFO:0009609
macrophage activation syndrome3MONDO:0015545EFO:1001806
language disorder3MONDO:0004750MONDO:0004750
bronchopulmonary dysplasia3MONDO:0019091MONDO:0019091
injury3MONDO:0021178EFO:0000546
stroke disorder3MONDO:0005098EFO:0000712
idiopathic pulmonary fibrosis3MONDO:0800504EFO:0000768
colitis3MONDO:0005292EFO:0003872
kidney failure3MONDO:0001106EFO:1002048
systemic lupus erythematosus3MONDO:0007915MONDO:0007915
erythema multiforme3MONDO:0006545EFO:1000694
ankylosing spondylitis2MONDO:0005306EFO:0003898
spondyloarthropathy2MONDO:0005095EFO:0000706
sinusitis2MONDO:0005961EFO:0007486
alcoholic hepatitis2MONDO:0001505EFO:1001345
neuromyelitis optica2MONDO:0019100EFO:0004256
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
myelodysplastic syndrome2MONDO:0018881EFO:0000198
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
Burkitt lymphoma2MONDO:0007243EFO:0000309
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
neoplasm2MONDO:0005070EFO:0000616
polyp2MONDO:0005079EFO:0000662
melanoma2MONDO:0005105EFO:0000756
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
appendicitis2MONDO:0005649EFO:0007149
hantavirus infectious disease2MONDO:0005780EFO:0007295
nasal cavity polyp2MONDO:0006314EFO:1000391
immunoglobulin A vasculitis2MONDO:0019167EFO:1000965
plantar fasciitis2MONDO:0004833EFO:1001909
aplastic anemia2MONDO:0015909HP:0001915
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
myeloproliferative neoplasm2MONDO:0020076EFO:0002428
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
radiculopathy2MONDO:0002959MONDO:0002959
breast neoplasm2MONDO:0021100MONDO:0007254
ovarian cancer2MONDO:0008170MONDO:0008170
myelodysplastic/myeloproliferative disease2MONDO:0020077MONDO:0020077
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
familial lipoprotein lipase deficiency2MONDO:0009387MONDO:0009387
lymphoproliferative syndrome2MONDO:0016537MONDO:0016537
thrombotic thrombocytopenic purpura2MONDO:0018896MONDO:0018896
Fanconi anemia2MONDO:0019391MONDO:0019391
migraine disorder2MONDO:0005277MONDO:0005277
plasma cell neoplasm2MONDO:0004959EFO:0000200
osteoarthritis, knee2MONDO:0005416EFO:0004616
CD4+/CD56+ hematodermic neoplasm2MONDO:0019467EFO:0010580
atherosclerosis1MONDO:0005311EFO:0003914
drug-induced liver injury1MONDO:0005359EFO:1000905
noise induced hearing loss1MONDO:0013098EFO:1001254
myopathy1MONDO:0005336EFO:0004145
myasthenia gravis1MONDO:0009688EFO:0004991
stiff-person syndrome1MONDO:0008491EFO:0007498
immune system disorder1MONDO:0005046EFO:0000540
optic nerve disorder1MONDO:0002135MONDO:0002135
Kawasaki disease1MONDO:0012727EFO:0004246
Gaucher disease1MONDO:0018150Orphanet:77260
Parkinson disease1MONDO:0005180MONDO:0005180
ovarian hyperstimulation syndrome1MONDO:0011972MONDO:0011972
frontotemporal dementia1MONDO:0017276MONDO:0017276
DiGeorge syndrome1MONDO:0008564MONDO:0018923
radius fracture1MONDO:0005325EFO:0003957
intussusception1MONDO:0007835HP:0002576
follicular lymphoma1MONDO:0018906MONDO:0018906
Friedreich ataxia0MONDO:0100339MONDO:0100339

30 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 614.

Phase distribution

PhaseTrials
PHASE2161
PHASE3125
PHASE4110
Not specified97
PHASE2/PHASE340
PHASE137
PHASE1/PHASE233
EARLY_PHASE111

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02283996PHASE4RECRUITINGAdhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
NCT03098225PHASE4NOT_YET_RECRUITINGA Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves’ Orbitopathy
NCT04826237PHASE4RECRUITINGOral Statins and Protection From Hearing Loss
NCT05097976PHASE4RECRUITINGMedrol Dosepak for Outpatient Total Knee Arthroplasty
NCT05867329PHASE4RECRUITINGFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
NCT05927233PHASE4RECRUITINGEffect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery
NCT06040255PHASE4ENROLLING_BY_INVITATIONFocal Cerebral Arteriopathy Steroid Trial
NCT06268704PHASE4RECRUITINGParticulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection
NCT06762145PHASE4NOT_YET_RECRUITINGEArly Effect of Glucocorticoid on Incidence of Persistent Left BundlE Branch Block (LBBB) Post-TAVR (EAGLE-TAVR Trial)
NCT06892197PHASE4RECRUITINGComparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)
NCT06892210PHASE4RECRUITINGComparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
NCT06968507PHASE4RECRUITINGComparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
NCT07077486PHASE4RECRUITINGEffects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
NCT07101445PHASE4RECRUITINGEvaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
NCT07180277PHASE4NOT_YET_RECRUITINGMethylprednisolone for Moderate to Severe Traumatic Brain Injury
NCT07255248PHASE4RECRUITINGHoffa’s Fat Pad Impingement (HFPI)
NCT07258771PHASE4RECRUITINGUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
NCT07265258PHASE4NOT_YET_RECRUITINGA Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
NCT07394894PHASE4NOT_YET_RECRUITINGLocal Percutaneous Pulsed Radiofrequency Ablation Versus Ultrasound Guided Steroids Injection in Management of Pain in Cases of Chronic Planter Fascitis, Randomised Double Blinded Study
NCT00037115PHASE4WITHDRAWNInduction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
NCT00048165PHASE4COMPLETEDA Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation
NCT00127985PHASE4UNKNOWN6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome
NCT00149994PHASE4COMPLETEDCyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
NCT00261820PHASE4COMPLETEDStudy Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
NCT00281710PHASE4COMPLETEDUrinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans
NCT00307671PHASE4COMPLETEDTreatment of Necrotizing Vasculitides for Patients Older Than 65 Years
NCT00396747PHASE4COMPLETEDA Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study
NCT00427388PHASE4UNKNOWNSteroids In caRdiac Surgery Trial (SIRS Trial)
NCT00492466PHASE4COMPLETEDInvestigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
NCT00493116PHASE4COMPLETEDIs IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
NCT00627731PHASE4COMPLETEDOral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients
NCT00717470PHASE4COMPLETEDA Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection
NCT00753792PHASE4COMPLETEDOral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse
NCT00908583PHASE4COMPLETEDDesensitization in Kidney Transplantation
NCT00908713PHASE4COMPLETEDCorticoids in Severe Community-Acquired Pneumonia (CAP)
NCT00915473PHASE4COMPLETEDGreater Occipital Nerve Block for Migraine Prophylaxis
NCT00957801PHASE4COMPLETEDAnabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men
NCT00968578PHASE4COMPLETEDEffects of Methylprednisolone After Total Knee Arthroplasty
NCT00968903PHASE4COMPLETEDEffects of Methylprednisolone After Total Hip Arthroplasty
NCT01000610PHASE4COMPLETEDA Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

177 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ProgesteroneChEMBL + PubChemPhase 4 (approved)NR3C1, TRPC5
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot